Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 4, 2010, Pages 482-489

  Kasamon, Yvette L ^a   Luznik, Leo ^a   Leffell, Mary S ^a   Kowalski, Jeanne ^a   Tsai, Hua Ling ^a   Bolaños Meade, Javier ^a   Morris, Lawrence E ^b   Crilley, Pamela A ^c   O'Donnell, Paul V ^d   Rossiter, Nancy ^a   Huff, Carol Ann ^a   Brodsky, Robert A ^a   Matsui, William H ^a   Swinnen, Lode J ^a   Borrello, Ivan ^a   Powell, Jonathan D ^a   Ambinder, Richard F ^a   Jones, Richard J ^a   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BMT Group of Georgia   (United States)

^c HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic blood or marrow transplantation; Cyclophosphamide; Graft versus host disease; Human leukocyte antigen; Nonmyeloablative conditioning

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; WHOLE BODY RADIATION; BONE MARROW TRANSPLANTATION; DISEASE FREE SURVIVAL; GENETICS; GRAFT REJECTION; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; PROCEDURES; RECURRENT DISEASE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77649342341     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.011     Document Type: Article

References (38)

1. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15 (1997) 1767-1777
2. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29 (1990) 79-91
3. Ash R.C., Horowitz M.M., Gale R.P., et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 7 (1991) 443-452
4. Kawase T., Morishima Y., Matsuo K., et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implications for its molecular mechanism. Blood 110 (2007) 2235-2241
5. Kanda Y., Chiba S., Hirai H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 (2003) 1541-1547
6. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92 (1998) 3515-3520
7. Morishima Y., Yabe T., Matsuo K., et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 13 (2007) 315-328
8. Strauss G., Osen W., and Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128 (2002) 255-266
9. Eto M., Mayumi H., Tomita Y., et al. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 146 (1991) 1402-1409
10. Luznik L., Engstrom L.W., Iannone R., et al. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 8 (2002) 131-138
11. Luznik L., Jalla S., Engstrom L.W., et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98 (2001) 3456-3464
12. Mayumi H., Umesue M., and Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 195 (1996) 129-139
13. Mayumi H., Himeno K., Tanaka K., et al. Drug-induced tolerance to allografts in mice, XII: the relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation 44 (1987) 286-290
14. Luznik L., Bolanos-Meade J., Brodsky R., et al. Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent for prevention of acute and chronic graft-versus-host disease after myeloablative HLA-matched related and unrelated bone marrow transplantation (BMT). Blood 112 (2008) 28
15. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 8 (2002) 377-386
16. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14 (2008) 641-650
17. Schwartz R., and Dameshek W. Drug-induced immunological tolerance. Nature 183 (1959) 1682-1683
18. Burroughs L.M., O'Donnell P.V., Sandmaier B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14 (2008) 1279-1287
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
20. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114 (2009) 511-517
21. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 11 (2005) 945-956
22. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
23. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16 (1988) 1141-1154
24. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94 (1999) 496-509
25. Ihaka R., and Gentleman R.R. a language for data analysis and graphics. J Comput Graph Stat 5 (1996) 299-314
26. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112 (2008) 4371-4383
27. Larsen C.P., Elwood E.T., Alexander D.Z., et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381 (1996) 434-438
28. Anderson B.E., McNiff J., Yan J., et al. Memory CD4 + T cells do not induce graft-versus-host disease. J Clin Invest 112 (2003) 101-108
29. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4 + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111 (2008) 2476-2484
30. Kamiryo Y., Eto M., Yamada H., et al. Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 69 (2009) 5151-5158
31. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12 (2006) 828-836
32. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110 (2007) 433-440
33. Diaconescu R., Flowers C.R., Storer B., et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 104 (2004) 1550-1558
34. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
35. Le Blanc K., Remberger M., Uzunel M., et al. A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem cell transplantation. Transplantation 78 (2004) 1014-1020
36. de Lima M., Anagnostopoulos A., Munsell M., et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 865-872
37. Rodriguez R., Nademanee A., Ruel N., et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 12 (2006) 1326-1334
38. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21 (2003) 3940-3947